Nitroxyl Technology

Cardioxyl has developed industry leading expertise in nitroxyl (HNO) chemistry and biology, and is employing its nitroxyl chemistry platform to discover and develop novel, proprietary therapeutics targeting cardiovascular disease.
Read More

CXL-1020

Cardioxyl's lead clinical candidate, CXL-1020, is in development for acute decompensated heart failure. The compound is currently under investigation in a multi-center Phase I/IIa clinical trial.
Read More

News

11.18.09 Cardioxyl Pharmaceuticals announces pre-clinical results on lead clinical candidate, CXL-1020

10.29.09 Cardioxyl Pharmaceuticals announces late-breaker at American Heart Association Conference

09.15.09 Cardioxyl Pharmaceuticals presents new data at the 13th annual Scientific Meeting of the Heart Failure Society of America

09.10.09 Cardioxyl Pharmaceuticals to present data at two cardiology conferences

07.01.09 Cardioxyl Pharmaceuticals initiates phase I/IIa study in heart failure